NASDAQ:IART - Nasdaq - US4579852082 - Common Stock - Currency: USD
INTEGRA LIFESCIENCES HOLDING
NASDAQ:IART (1/24/2025, 8:00:02 PM)
After market: 26.05 0 (0%)26.05
+0.45 (+1.76%)
The current stock price of IART is 26.05 USD. In the past month the price increased by 18.36%. In the past year, price decreased by -37.74%.
New global medical education platform offers digital tools to keep HCPs at the forefront of medical knowledge...
The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior...
Integra LifeSciences' Q3 results show adjusted EPS of $0.41 and revenue at $380.83 million. Codman segment grows 1%, while Tissue Tech sees a 3.6% decline.
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company,...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 26.77 | 216.86B | ||
ISRG | INTUITIVE SURGICAL INC | 79.68 | 208.03B | ||
SYK | STRYKER CORP | 33.88 | 150.32B | ||
BSX | BOSTON SCIENTIFIC CORP | 43.19 | 150.24B | ||
MDT | MEDTRONIC PLC | 17.18 | 115.65B | ||
BDX | BECTON DICKINSON AND CO | 18.5 | 70.60B | ||
EW | EDWARDS LIFESCIENCES CORP | 25.84 | 40.69B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 21.01 | 40.51B | ||
RMD | RESMED INC | 30.22 | 36.77B | ||
IDXX | IDEXX LABORATORIES INC | 39.76 | 35.64B | ||
DXCM | DEXCOM INC | 52.21 | 34.67B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 19.9 | 25.26B |
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 3,946 full-time employees. The firm manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The firm provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.
INTEGRA LIFESCIENCES HOLDING
1100 Campus Road
Princeton NEW JERSEY 08540 US
CEO: Peter J. Arduini
Employees: 3946
Company Website: https://www.integralife.com/
Investor Relations: https://investor.integralife.com/
Phone: 16092750500
The current stock price of IART is 26.05 USD.
The exchange symbol of INTEGRA LIFESCIENCES HOLDING is IART and it is listed on the Nasdaq exchange.
IART stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for IART, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of IART.
IART does not pay a dividend.
IART will report earnings on 2025-02-19, after the market close.
The PE ratio for IART is 10.5. This is based on the reported non-GAAP earnings per share of 2.48 and the current share price of 26.05 USD.
The outstanding short interest for IART is 4.34% of its float.
ChartMill assigns a technical rating of 6 / 10 to IART. When comparing the yearly performance of all stocks, IART is a bad performer in the overall market: 60.38% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to IART. There are concerns on the financial health of IART while its profitability can be described as average.
Over the last trailing twelve months IART reported a non-GAAP Earnings per Share(EPS) of 2.48. The EPS increased by -21.27% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -0.16% | ||
ROE | -0.43% | ||
Debt/Equity | 0.79 |
ChartMill assigns a Buy % Consensus number of 52% to IART. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of -19.35% and a revenue growth 4.44% for IART